Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes

Hot Flashes Clinical Trial

Official title:

A Comparison of Hormonal Therapy: Tapering Regimens for Mediating Hot Flashes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00547001
• Other study ID #: SCHN002140HI
• Status: Recruiting
• Phase: N/A
• First received: October 17, 2007
• Last updated: July 17, 2008
• Start date: August 2007
• Est. completion date: November 2009

Study information

• Verified date: July 2008
• Source: Hartford Hospital
• Contact: Anna Lynne Hosig, RN
• Phone: 860-545-1005
• Email: LHOSIG[@]harthosp.org
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study will evaluate whether there is a difference in the proportion of women who report a worsening severity of their hot flashes between three tapering schedules for one accepted HT/ET regimen. Secondarily, we hope to evaluate whether there is a difference in the frequency (number of occurrences per week), severity (defined as a subjective scale mild, moderate, or severe), and "Severity Index" (SI, equaling the product of both) of hot flashes between three tapering schedules for one accepted HT/ET regimen.

Description:

A Comparison of Hormonal Therapy:

Tapering Regimens for Mediating Hot Flashes

Clinicians have been asking for years whether a tapering dose of HT would make a difference in the frequency and severity of vasomotor symptoms after menopausal women stop HT therapy. This planned randomized, placebo-controlled trial (RCT) seeks to evaluate whether there is a difference in the proportion of women who report a worsening severity of their hot flashes between three tapering schedules for one accepted HT/ET regimen. Secondarily, we hope to evaluate whether there is a difference in the frequency (number of occurrences per week), severity (defined as a subjective scale mild, moderate, or severe), and "Severity Index" (SI, equaling the product of both) of hot flashes between three tapering schedules for one accepted HT/ET regimen.

All participants will be randomized to one of the three arms (taper arm, placebo arm, and "cold turkey" arm). Each patient's gynecologist will be aware of the patient's involvement in the study and will assist by providing baseline safety information. All patients will be taken off their current HT/ET regimen and will be placed on study medication (1 mg of Estradiol PO every day for 8 weeks, "stabilization" phase). After the 8-week stabilization period, all participants will begin the therapy corresponding to the arm to which they were randomized. Each patient in the taper or placebo arm will take one capsule per day. The patients in the "cold turkey" arm will discontinued acutely after the stabilization.

The patients will keep a diary of the number and frequency of symptoms during the study. Patients will be contacted by phone to confirm that they are completing their diaries and that they have not developed side effects or complications that could force their discontinuation from the study.

Patients will be followed for several additional weeks, after discontinuation from treatment or placebo, to monitor for symptoms. At the end of the study, our coordinator will contact the patient to assure that Medroxyprogesterone acetate, MPA, was taken properly by those women who have a uterus. They will also confirm that no other symptoms, complications, or questions have arisen. At that time, they will be able to return to their prior therapy as deemed appropriate by them and their physician.

Patients will be recruited by invitation upon presenting for care to their physician. With invitations at recruitment, all patients will be given a study form. Reasons for ineligibility or refusal will be noted. After expressing interest, the physician or practice of record will sign a form acknowledging that their patient has had an annual physical exam (including pelvic exam) within the last 12 months and that a mammogram has been reported as negative (BIRADS I or II) within the last 24 months. An appointment will be made with one of our study personnel or coordinators. The patient will bring the signed form to this visit. At this enrollment / consent visit, their eligibility criteria will be reviewed. All patients will sign the informed consent, and be randomized to a group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 235
• Est. completion date: November 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 35 Years to 70 Years

Eligibility

Inclusion Criteria:

• Female.

• ages 35-70, inclusive.

• Postmenopausal (Natural or surgical: see definitions).

• Currently on HT/ET for at least 6 months for vasomotor symptomatology.

• Vasomotor symptoms are currently controlled on medication .

• An annual physical & pelvic exam has been performed within the last 12mo

• The patient has had a normal mammogram(BIRADS I/II) within the last 24mo

Exclusion Criteria:

• Males

• Hypertension, defined as either SBP >140 mmHg or DBP >90 mmHg

• Lack of compliance (willingness to adhere to protocol)

• Inability or unwillingness to swallow pills

• Patients with any contraindications to HT/ET

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hot Flashes
• Night Sweats

Intervention

Drug:
• Estradiol
1mg during stabilization & then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.

Locations

Country	Name	City	State
United States	Hartford Hospital	Hartford	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Hartford Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate whether there is a difference in the proportion of women who report a worsening severity of their hot flashes between three tapering schedules for one accepted HT/ET regimen.		During the tapering and post taper time period.
Secondary	frequency, severity, and "Severity Index" of hot flashes.		During the tapering and post taper time period.